期刊
ADVANCED MATERIALS
卷 30, 期 30, 页码 -出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/adma.201704490
关键词
dual-responsiveness; nitric oxide; prodrug delivery; safe treatment; tumor therapy
类别
资金
- National Natural Science Foundation of China for Innovative Research Groups [51621002]
- National Key Research and Development Program of China [2016YFA0203700]
- NSFC [51572083, 51461165202, 51472085]
- Program of Shanghai Academic/Technology Research Leader [18XD1401400]
- Basic Research Program of Shanghai [17JC1404702]
- Shanghai Rising-Star Program [16QA1401300]
- 111 project [B14018]
- Fundamental Research Funds for Central Universities [222201718002]
Chemotherapy suffers numbers of limitations including poor drug solubility, nonspecific biodistribution, and inevitable adverse effects on normal tissues. Tumor-targeted delivery and intratumoral stimuli-responsive release of drugs by nanomedicines are considered to be highly promising in solving these problems. Compared with traditional chemotherapeutic drugs, high concentration of nitric oxide (NO) exhibits unique anticancer effects. The development of tumor-targeting and intratumoral microenvironment-responsive NO-releasing nanomedicines is highly desired. Here a novel kind of organic-inorganic composite nanomedicine (QM-NPQ@PDHNs) is presented by encapsulating a glutathione S-transferases (GST)-responsive drug O-2-(2,4-dinitro-5-{[2-(-d-galactopyranosyl olean-12-en-28-oate-3-yl)-oxy-2-oxoethyl] piperazine-1-yl} phenyl) 1-(methylethanolamino)diazen-1-ium-1,2-dilate (NPQ) as NO donor and an aggregation-induced-emission (AIE) red fluorogen QM-2 into the cores of the hybrid nanomicelles (PEGylated disulfide-doped hybrid nanocarriers (PDHNs)) with glutathione (GSH)-responsive shells. The QM-NPQ@PDHN nanomedicine is able to respond to the intratumoral over-expressed GSH and GST, resulting in the responsive biodegradation of the protective organosilica shell and NPQ release, and subsequent NO release within the tumor, respectively, and thus normal organs remain unaffected. This work demonstrates a paradigm of dual intratumoral redox/enzyme-responsive NO-release nanomedicine for tumor-specific and high-efficacy cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据